A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Latest Information Update: 25 May 2025
At a glance
- Drugs Daratumumab (Primary) ; Lenalidomide (Primary) ; Talquetamab (Primary) ; Teclistamab (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms MajesTEC-7
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 04 Jun 2024 Results(As of Nov 27, 2023, n=26 pts ) of the first safety run-in (SRI) from MajesTEC-7 , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2024 Results presented in a Johnson & Johnson Media Release.
- 03 Jun 2024 According to a Janssen Media Release, the data from this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.